ABSTRACT The relevance of zinc in resistance to infections by virus, fungi and bacteria is recognized because of its pivotal role in the efficiency of the entire immune system, in particular in conferring biological activity to a thymic hormone called thymulin, which has differentiation properties on T-cell lines. In infection with human immunodeficiency virus (HIV), the zinc-bound form of thymulin (active thymulin, ZnFTS) is strongly reduced in stage IV of the disease (Centers for Disease Control and Prevention classification) with concomitant decrements in CD4 ϩ cell count and zincemia values. The zinc-unbound form of thymulin (inactive thymulin, FTS) is, in contrast, very high. The in vitro addition of zinc to plasma samples induces a recovery of the thymulin active form, suggesting low zinc bioavailability as the cause of impaired thymic functions with consequent CD4 ϩ depletion. An analysis of risk factors for the incidence of recidivism opportunistic infections shows CD4 ϩ depletion and zinc deficiency to have significant scores. Supplementation with zinc for 1 mo (45 mg Zn 2ϩ /d) associated with zidovudine (AZT) therapy in stage IV induces recovery of active zinc-bound thymulin, of zincemia, of CD4 ϩ cells with concomitant reduction (50%) of recidivism opportunistic infections compared with the AZT-treated group. Complete disappearance of recidivism by Candida aesophagea or Pneumocystis carinii is observed after supplementation with zinc. The relative risk factors (CD4 ϩ depletion and zinc-deficiency) have lower scores in the HIV-positive zinc-treated group, confirming, as such, the relevance of zinc in opportunistic infections that involve extracellular matrix. Such an assumption is indirectly confirmed with new HAART, where no opportunistic infections occur. Indeed, HIV RNA is inversely correlated with both CD4 ϩ and zincemia values (r ϭ Ϫ0.73, P Ͻ 0.01) in HAART-treated subjects. Lower scores for the same relative factors for the appearance of opportunistic infections are present in HAART-treated subjects compared with those treated with AZT. These findings, on the one hand, show the poor efficacy of AZT therapy compared with HAART therapy for the progression of HIV, but on the other hand, they suggest that the lack of occurrence of opportunistic infections by HAART may also result from major zinc bioavailability. This further supports the key role played by zinc against opportunistic infections in HIV with a possible independent effect by either HIV or the pathogens involved.
Zinc is a relevant trace element in the body (Mills 1989) . Among the most relevant findings are the listing of zinc as a catalytic component of Ͼ200 enzymes, its requirement as a structural constituent of many proteins and, likely, its function in preventing free radical formation. The ensuing relevance for cell division and differentiation, as well as for programmed cell death, for gene transcription, for biomembrane functioning, and obviously for many enzymatic activities, has led to the consideration of zinc as a leading element in ensuring correct functioning of various tissues, organs and systems . Experimental evidence in humans and animals has demonstrated that zinc deficiency leads to a plethora of body homeostatic mechanism dysfunctions with consequent slowed growth, susceptibility to many diseases and decreased survival rates that can be corrected with zinc supplementation (Mocchegiani et al. 1998 , Prasad 1991 . A central clinical feature of zinc deficiency is the increased susceptibility to infectious diseases. This led researchers to speculate that zinc must be important for host immunity. Indeed, the past two decades have witnessed a rapid growth in knowledge of the underlying mechanisms whereby zinc exerts its ubiquitous effects on immune function, disease resistance and general health (Walsh et al. 1994 , Zalewski 1996 . In particular, zinc is essential for thymic functions by means of a 0022-3166/00 $3.00 © 2000 American Society for Nutritional Sciences.
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zinc-dependent thymic hormone called thymulin (ZnFTS) 4 (Dardenne et al. 1982) , which is indispensable for the differentiation and maturation of T cells (Goldstein 1984) . In the course of infection, derangements of the immune functions at both central and peripheral levels are usual and constant events associated with more or less marked zinc deficiency (Shankar and Prasad 1998) .
The aim of the present article was to summarize data from our laboratory regarding the role of zinc in stage IV of human immunodeficiency virus (HIV) infection according to the Centers for Disease Control and Prevention classification (Centers for Disease Control AIDS Program 1987) because marked zinc deficiency and strong compromised immune functions are present with the consequent appearance of opportunistic infections by various pathogens leading to death of the infected individual (Fabris et al. 1988 , Levy 1989 . Supplementation with zinc associated with zidovudine (AZT) therapy (retrospective study) is discussed in comparison with new HAART therapy.
Zinc, immune system and infections
Numerous data in experimental animals support the existence of a crucial role played by zinc in immunocompetence (Chandra 1983 , Wellinghausen et al. 1997 ). The major abnormalities during zinc deficiency in immune responses are in T-lymphocyte and neutrophil functions. Zinc deficiency in animals causes thymic and lymph node atrophy, impaired cell-mediated cutaneous hypersensitivity reactions, decreased response to mitogen [phytohemagglutinin (PHA)] and depression of T-cell-dependent antibody production. Furthermore, a zinc-deficient diet in experimental animals causes impaired T-helper and T-suppressor functions and decreased T-killer and natural killer activity (Iwata et al. 1979 ) ( Table 1) . Assessment of the role of zinc in the development and function of different lymphoid cell populations indicates that this element has an effect predominantly on T-lymphocytes (Miller and Strittmatter 1992) and macrophages (Wirth et al. 1989) , and less on B-lymphocytes (Cook-Mills and Fraker 1993) , although for this latter lymphocyte population, an effect of zinc deficiency was documented on IgG production but secondary to T-dependent antibody response (Forbes et al. 1991) . In humans from more or less zinc deficiency, depressed immune functions both at central and peripheral levels, particularly decreased thymic endocrine activity, reduced Thelper functions and impaired natural killer activity, are constant events (Chandra 1983 , Wellinghausen et al. 1997 , confirming, as such, the predominant role of zinc deficiency in affecting cell-mediated immunity.
Decreased chemotaxis by neutrophil and monocytes is also observed in zinc deficiency (Fraker et al. 1986 ). The effect of zinc deficiency is mainly addressed, other than regarding the growth and development of CD4 ϩ cells (Miller and Strittmatter 1992) , regarding cytokine production relevant for T-lymphocyte and macrophage functions. In particular, the production of interleukin (IL)-2, IL-12, interferon (IFN)-␣, and IFN-␥ is decreased (Dowd et al. 1986, Sala and Kirchner 1987) and the production of tumor necrosis factor (TNF)-␣, IL-1, and IL-6 is increased during zinc deficiency (Beck et al. 1996 , Cui et al. 1998 (Table 1) . In this context, a relevant point is related to findings showing that zinc affects more than Th1 (cell-mediated immunity) believed necessary for IL-2 and IFN-␥ release rather than Th2 cells (antibody-mediated immunity) believed necessary for IL-4, IL-6, IL-10, and IL-13 release . With regard to macrophages, the cytokine production (IL-1␤, IL-6, TNF-␣, IL-12) altered in zinc deficiency is normalized by in vitro zinc addition (Driessen et al. 1994 ). Recently, it was shown that zinc also affects the major histocompatibility complex (MHC) class II molecules with opposite effects, preventing or making easier the antigen presentation from superantigen noxae, such as Mycoplasma or toxins, respectively (Driessen et al. 1995) .
These findings clearly suggest the relevance of zinc deficiency for immune depression with the onset of many pathologies, among which infectious episodes are the most frequent (Clegg et al. 1989) . Indeed, numerous animal and human studies indicate that zinc deficiency decreases resistance to infection diseases. Zinc-deficient animals and humans have depressed immune response (Chandra 1983 , Iwata et al. 1979 , Wellinghausen et al. 1997 (Table 1) , and they are more susceptible to a diverse range of infectious pathogens, including viruses, bacteria, fungi and protozoa (Table 1 ). The role of zinc deficiency during infection is broad: from a delay in production of protective IgG antibodies to decreased T-lymphocyte activation and in some cases (e.g., for infections by Plasmodium yoelii) to death (for a review, see Shankar and Prasad 1998 ). An adequate zinc diet in animals is able to correct the impaired resistance to infections with a reduction in infectious episodes ( Table 2) .
Several studies have demonstrated the benefits of zinc supplementation in infectious episodes of various congenital and acquired diseases in humans. In particular, supplementation with zinc is able to significantly reduce infectious episodes (45-50%) at the bronchoalveolar level in preschool children (Sazawal et al. 1998 ) and in Down syndrome subjects (Licastro et al. 1994 ). Significant reductions in infectious episodes by supplementation with zinc are also observed in leprosy, malaria, chronic diarrhea, congenital herpes, malnutrition and acrodermatitis enteropathica ( Table 2 ), in that it occurs for the latter in natural bovine acrodermatitis enteropathica, where the impaired resistance to viruses, fungi and bacteria is corrected by increased dietary zinc intake (Good 1989 ). All of this findings support the idea of a key role played by zinc in the efficiency of immune responses against infectious episodes. To confirm this role of zinc, we used an HIV model (stage IV of disease, Centers for Disease Control and Prevention classification, Centers for Disease Control AIDS Program 1987) because zinc deficiency, deranged immune functions and occurrence or recidivism of opportunistic infections are usual and constant events with an unfavorable prognosis (Fabris et al. 1988 , Levy 1989 ).
Zinc and HIV
More or less marked zinc deficiency has been observed in HIV infection at various stages of diseases (Fabris et al. 1988) , as well as in the first phases of HIV infection (Baum et al. 1995) . Therefore, zinc deficiency may be a cofactor for the progression of the disease (Falutz et al. 1988) , despite the report that zinc deficiency is not a common contributory factor for HIV infection or clinical expression and that HIV infection does not induces zinc deficiency (Walter et al. 1990 ). However, a general consensus exists on the presence of malnutrition, intestinal absorption, changes in metabolic handling of nutrients and increased energy expenditure in the setting of HIV infection (Beisel 1995 , Kotler 1989 , Sauerwein 1993 , with all of these characteristics causing zinc deficiency in both humans and animals Mocchegiani 1998, Mills 1989 ). On the other hand, reduced appetite and decreased dietary intake are prominent features of HIV infection, so it is therefore not surprising to find zinc deficiency in HIV-positive patients, particularly those with advanced stages of the disease (Odeh 1992) . Several other factors may also contribute to zinc deficiency. HIV infection is associated with acute and chronic infections with various types of viral, bacterial, fungal or parasitic pathogens (Fauci et al. 1984 ). These infections may cause zinc deficiency, and this can last for a long period of time, depending on the cause (Sugarman 1983) .
Taking into account the pivotal role of zinc in the efficiency of the immune system (Chandra 1983 , Prasad et al. 1988 , Wellinghausen et al. 1997 , in particular for CD4
ϩ cell growth and function (Miller and Strittmatter 1992) , the strong depletion of CD4 ϩ cells in the setting of HIV infection leading to the appearance or recidivism of opportunistic infections, followed by an unfavorable prognosis (Fauci et al.) , may be in large part due to the low zinc bioavailability. Such an assumption may be supported by the discovery that zinc is also required for the biological activity of the thymic hormone ZnFTS (Dardenne et al. 1982 ) that is indispensable for the differentiation and maturation of CD4 ϩ cells (Goldstein 1984) . The zinc-unbound form of thymulin (FTS) is inactive with an inhibitory effect on the zinc-bound active form (Zn-FTS) (Fabris et al. 1984) . The in vitro zinc addition to plasma samples unmasks the inactive form (FTS), showing the total amount of thymulin molecules produced (ZnFTS ϩ FTS) (Fabris et al. 1984) . The ratio between total thymulin (TT) and active thymulin (AT) represents the thymulin-unsaturable fraction by zinc ions and, as such, is a good marker with which to test real zinc deficiency (TT/AT Ͼ 2 ϭ marked zinc deficiency; TT/AT Ͻ 2 ϭ mild zinc deficiency; TT/AT ϭ 1n zinc values) (Fabris et al. 1984) . This phenomenon (TT/AT Ͼ 2) occurs in many zinc deficiencies, including HIV stage IV, suggesting that the thymic defect in thymulin production is not intrinsic but is in large part dependent on the low peripheral zinc bioavailability to saturate all thymulin molecules produced (Fabris et al. 1984 . In this context, discrepancies exist in older literature regarding decrements in thymic hormone production in HIV infection. Thymosin ␣-1 is increased (Naylor et al. 1983 ), whereas thymulin is decreased (Dardenne et al. 1983 , Incefy et al. 1986 ). In agreement with Dardenne et al. 1983 and Incefy et al. 1986 , in a retrospective study where only AZT was available, AT is strongly reduced in stage IV (10 young patients), whereas inactive thymulin (FTS) is strongly increased compared with young healthy control subjects. The in vitro zinc addition to plasma samples unmasks FTS-inactive mole- The zinc-adequate diet in experimental animals was carried out for 2-3 mo. Supplementation with zinc in humans was carried out for 1-2 mo at physiological dose (USDA 1976) . The data for percent reduction in experimental animals was obtained 2 months before and at the end of zinc-adequate diet. The data for humans was obtained 6 mo or 1 y before and 6 mo or 1 y after zinc supplementation.
cules, showing that the total amount of thymulin (ZnFTS ϩ FTS) is near the young normal subject range . The TT/AT ratio is Ͼ 2 (4-5 log Ϫ2 ) in stage IV, suggesting that the severe zinc deficiency present in this stage of disease (70 -75 g/dL) is real (Fabris et al. 1988 . Concomitantly, very strong CD4 ϩ depletion is observed at individual level increments of 70% of recidivistic opportunistic infections by various pathogens on d 120 of observation are also present . These findings suggest that the marked zinc deficiency in stage IV may be the cause of deranged immune functions with the consequent increased appearance of recidivistic opportunistic infections. On the other hand, the thymus gland is also atrophic in the first phases of HIV infection (Gaulton et al. 1997) due to increased apoptosis of thymocytes (Meyaard et al. 1992) . Zinc prevents apoptosis (Fraker and Telford 1997) . The same mechanisms that involve apoptosis in atrophic thymus have been recently proposed in aging because zinc in vitro prevents old thymocyte apoptosis (Provinciali et al. 1998) , and supplementation with zinc in old mice restores thymic functions and the number of thymocyte CD4 ϩ cells . These last findings clearly suggest the key role played by zinc in thymic functions with the consequent differentiation and maturation of CD4 ϩ cells. Because the analysis of risk factors (Cox hazard regression) for infection incidence in stage IV confirms zinc deficiency and CD4 ϩ depletion as risk factors with significant scores (Table 3) , this is further support that the low zinc bioavailability is crucial for CD4 ϩ depletion and, consequently, for HIV progression, suggesting supplementation with zinc in this stage of disease.
In this context, there is no general consensus for supplementation with zinc in HIV infection for many reasons, which are dependent on the dose of zinc that is used. First, a high zinc intake induces a rapid progression of HIV infection mainly due to the competition phenomenon with copper inducing hypocupremia, anemia, leukopenia and neutropenia with, obviously, further immune derangement (Tang et al. 1996) . Second, during the acute phase response, zinc is redistributed from plasma to liver and to lymphocytes (Beisel 1995) , being an adaptive response intended to deprive invading pathogens of zinc (Clohessy and Golden 1996) . Because the liver is a site of the extrathymic T-cell pathway prominent during infections (Abo 1993 ) and because zinc is also relevant for this pathway , supplementation with zinc might not be necessary as previously suggested (Walter et al. 1990 ). However, the main reason zinc supplementation is not suggested is related to the discovery that HIV-Tat protein and HIV-nucleocapsid protein NCp7 are strongly zinc dependent with high binding affinity (Frankel et al. 1988 , Melly et al. 1996 and both proteins are relevant for HIV replication (Fisher et al. 1986 , Frankel et al. 1988 , Mely et al. 1996 . Thus, major zinc bioavailability by supplementation with zinc might induce a major activation of Tat and NCp7 proteins with consequent quick viral HIV replication and rapid HIV progression. However, recent discoveries showing zinc finger motifs required for inactivation of HIV replication by means of gag precursors (Mizuno et al. 1996 , Turpin et al. 1996 , as well as a novel zinc finger protein (KOX 1) as a protective agent against HIV replication at intracellular level (Thiesen 199661) and, finally, the capability of zinc to prevent the loss of CD4 ϩ lymphocytes in an in vitro HIV feline model (Johnson et al. 1996) , suggest that the low zinc bioavailability in HIV infection may have more of a harmful rather than a beneficial role for disease progression. Supplementation with zinc may be useful to block and, as such, to stabilize the disease with possibly no recidivism opportunistic infections.
A further support for the beneficial effect of zinc supplementation comes from the findings showing a zinc-binding protein, such as ␣ 2 -macroglobulin with high zinc binding affinity , to strongly increase during infections with Pseudomonas aeruginosa (Fitzgerald and Pastan 1993) and, as such, may be a marker for the appearance of acute phase infections (Roberts et al. 1982) . Impaired immune functions are also present during infections with P. aeruginosa in patients affected by burns (Berger et al. 1998) and cystic fibrosis . Despite ␣ 2 -macroglobulin having been suggested as protective against bacteria endotoxins with a killing mechanism (Fitzgerald and Pastan 1993) , its abnormal increments may become deleterious for the efficiency of the immune system through continuous sequestering of zinc (Mocchegiani et al. 1999) . Physiological supplementation with zinc in burned men (Berger et al. 1998 ) recovers immune efficiency with a significant decrease in the number of bronchopneumonia infections (Berger et al. 1998) . These last findings clearly suggest that supplementation with zinc does not induce a possible further deleterious role of ␣ 2 -macroglobulin because this zinc-binding protein may be completely saturated by preexisting zinc ions, as occurs in cancer (Mocchegiani et al. 1999) . Indeed, the increased ␣ 2 -macroglobulins in cancer are not affected by supplementation with zinc, which induces, by contrast, a beneficial effect on immune functions with an ␣ 2 -macroglobulin protective role (Mocchegiani et al. 1999) . The same mechanism might also occur in HIV infection, where physiological supplementation with zinc might not induce a further viral replication because both Tat and NCp7 zinc-binding proteins might be completely saturated by preexisting zinc ions. Thereby, zinc may be available for inhibitory action by gag precursors (Mizuno et al. 1996 , Turpin et al. 1996 and for immune efficiency recovery with consequent opportunistic infection reduction. Such an hypothesis is supported by the fact that up-physiological supplementation with zinc at stage III of the disease, at the borderline for the appearance of the first opportunistic infections (Fauci et al. 1984 ) also showing, in many cases, a high viral load (Mellors et al. 1996) , is able to prevent the onset of a first opportunistic infection for a long period of time (ϳ2 y), postponing HIV progression .
Supplementation with zinc in HIV stage IV
Supplementation with zinc (at the dosage of 45 mg Zn 2ϩ /d) (three times the recommended daily allowance; USDA 1976) concomitant with AZT therapy in stage IV (12 young patients) carried out from the time of recruitment (time 0) for 1 mo induced an increment of CD4 ϩ cells (from 80 Ϯ 10 mm 3 at time 0 to 121 Ϯ 9 mm 3 at d 120 of observation from time 0), a restoration of both TT/AT ratio (2-2.5 log Ϫ2 ) and zincemia value; reductions (50%) in recidivistic opportunistic infections at time 120 are also observed . The more relevant point is related to complete disappearance of recidivistic opportunistic infections by C. aesophagea and P. carinii in a zinc-treated group . These findings suggest that the dose of zinc (three times the recommended daily allowance) is not toxic because no side effects are observed , but it is beneficial against the appearance of recidivistic opportunistic infections that involve the extracellular matrix (Singh et al. 1992) . Prolonged survival compared with the untreated group also occurs . Such an assumption is confirmed by an analysis of risk factors (CD4 ϩ depletion and zinc deficiency) in stage IV for recidivistic opportunistic infections after supplementation with zinc showing significant reductions in scores (Table 3) . Although the number of CD4 ϩ cells is still strongly reduced (121 Ϯ 9 mm 3 ) after zinc supplementation, its score as a relative risk factor is not significant. This latter fact may suggest the possible presence of a low viral load in zinc-treated group compared with the zinc-untreated group (viral load was not tested due to the lack of availability of an HIV RNA technical procedure in this retrospective study). Although these findings further confirm the measure of CD4 ϩ as misleading to predict HIV progression compared with viral load (Mellors et al. 1996) , they may suggest a role of zinc HIV replication by means of gag precursors (Frankel et al. 1988 , Mely et al. 1996 , despite the strong CD4 ϩ depletion remaining very evident after supplementation with zinc compared with values of young healthy control subjects (965 Ϯ 68 mm 3 ). Few zinc trials have been carried out in HIV infection in the 1990s. Some articles have, however, reported a beneficial effect of supplementation with zinc (135 mg zinc gluconate/d for 15 d corresponding to 40 mg Zn 2ϩ /d) on the recovery of immune efficiency (CD4 ϩ cells and PHAmitogen responsiveness) in stage IV of HIV infection (Zazzo et al. 1989 ). General good health as revealed by increments of body weights (Isa et al. 1992 ) and increased survival (Baum et al. 1995) are also associated. Although these studies have been carried out in small cohorts of HIV subjects, they are suggestive to give a pivotal role to zinc in HIV infection to thwart the appearance of opportunistic infections.
Further indirect support for this assumption comes from the new HAART therapy. Other HIV subjects (10 subjects in stage IV with CD4 ϩ cells of Յ 100 mm 3 ) treated with new HAART showed significant increments of CD4 ϩ cells and zincemia values associated with significant decrements of the viral load (HIV RNA) (tested with reverse transcriptionpolymerase chain reaction technical procedure, Mellors et al. 1996) . No appearance occurred of recidivistic opportunistic infections during 4 mo of observation (Table 4) . Furthermore, significant inverse correlations exist between CD4 ϩ and HIV RNA (r ϭ Ϫ0.79, P Ͻ 0.01) but also between zincemia and HIV RNA (r ϭ Ϫ 0.73, P Ͻ 0.01) in HAART-treated subjects. This suggests that in addition to increasing CD4 ϩ cells (Chaisson and Moore 1997) , the new HAART therapy may thwart the appearance of recidivistic opportunistic infections (Chaisson and Moore 1997) , also through major zinc bioavailability. As such, zinc is crucial against infections in both stage III and stage IV, which is critical for an unfavorable prognosis (Fabris et al. 1988 , Fauci et al. 1984 , Levy 1989 . The same relative risk factors also show significant reduction of scores in HAART-treated patients compared with AZT-treated patients (Tables 3 and  5) . Because HIV RNA has been show as a real predictor for HIV progression and, consequently, the development of new HAART therapy (Chaisson and Moore 1997, Mellors et al. 1996) , the presence of a nonsignificant score for HIV RNA in HAART-treated subjects is confirmation (Table 5) . Zinc is absent in HAART drugs (protease inhibitors) (S. Veccia, personal communication). Thus, the mechanism or mechanisms via which HAART may induce zinc increments are still unknown. Decreased acute inflammation (Chandra 1992) or major zinc intestinal absorption may occur as revealed by significant increments in body weight in HAART-treated subjects (Table 4) .
Although these findings further support the idea of poor efficacy of AZT for HIV progression compared with new HAART therapy (Hazura and Porter 1996) despite the presence of latent HIV in CD4 ϩ cells during this therapy (Chun et al. 1997) , they also further suggest the key role played by zinc in resistance against infections, as recently proposed (Shankar and Prasad 1998) . Such a key role may be independent of the HIV and the pathogens involved.
Future remarks
On the basis of the present report, the following points may be stressed: 1) Severe zinc deficiency is present in stage IV of HIV infection associated with a strongly compromised immune system with the appearance of many recidivistic opportunistic infections that lead to death of the individual. Such severe zinc deficiency and CD4 ϩ depletion have significant scores as relative risks for recidivistic opportunistic infections, suggesting that such an appearance may be also due to zinc deficiency.
2) Supplementation with zinc (three times the recommended daily allowance) for 1 mo induces at individual levels significant reductions (50%) in recidivistic opportunistic infections with complete disappearance of recidivism by C. aesophagea and P. carinii with a role for zinc more involved in extracellular matrix. The significant reduction in scores in relative risk factors (CD4 ϩ depletion and zinc deficiency) after supplementation with zinc is in line with the proposed pivotal role of zinc in resistance to infection (Chandra 1989, Shankar and Prasad 1998) . Because of the significant inverse correlation between zincemia and HIV RNA in HAART-treated subjects with no appearance of opportunistic infections, it is further indirect evidence of that. Thus, zinc is important to induce resistance to infections. However, supplementation with zinc must be carried out with caution and for short periods because high doses of zinc are dangerous due to toxic effects on immune functions as a result of competition phenomenon with copper (Chandra 1984 , Fosmire 1990 . Such an aspect is relevant in stage IV, where the immune system is strongly compromised. In addition, high doses of zinc might also effectively induce a quick viral replication by means of Tat or NCp7 proteins and, as such, justify the lack of benefit of high doses of zinc in HIV infection reported by others (Tang et al. 1996) . By contrast, physiological or up-physiological supplementation with zinc for short periods may be beneficial, as demonstrated in stage III with postponement of HIV progression (Isa et al. 1992 , Zazzo et al. 1989 .
Taking into account the relevant role of zinc in thymic functions (Dardenne et al. 1982) and peripheral immune efficiency (Chandra 1983, Fabris and , recidivistic opportunistic infection reductions after zinc supplementation may occur by means of thymic endocrine activity restoration, which, in turn, promote a major homing of stem cells from the bone marrow (Fabris et al. 1997 ) and might induce recovery of CD4 ϩ cell number. The restoration of thymic endocrine activity followed by CD4 ϩ increments and relative risk factor reductions after supplementation with zinc is in line with this interpretation.
Alternatively, other direct or indirect mechanisms for CD4 ϩ recovery may be taken into account. A direct effect of zinc in preventing apoptosis of CD4 ϩ cells by means of endonuclease enzymes with a cleavage mechanism or by means of c-myc may be involved, although such a prevention may be dependent on intracellular zinc concentrations (Fraker and Telford 1997) . Indirectly, zinc might reduce CD4 ϩ apoptosis by means of its influence on immune cells to produce various cytokines, such as IFN-␣, which in turn may prevent CD4 ϩ apoptosis induced by bacteria endotoxins by means of its transcription factors IRF-1 and IRF-2 (Lopez- Collazzo et al. 1998) . Zinc, by means of the inhibition of nuclear factorB (Shumilla et al. 1998) , which is under the control of TNF-␣ (Beg and Baltimore 1996) , might prevent CD4 ϩ apoptosis induced by TNF-␣ (Beg and Baltimore 1996) . Indeed, TNF-␣ is strongly increased in HIV infection and, as such, is suggested as a prognostic factor for HIV progression (Odeh 1992) . Moreover, zinc may have also a direct action as an antioxidant by means of nitric oxide, which in turn induces zinc release from metallothioneins and so may limit free radical membrane damage during inflammation (Shankar and Prasad 1998) . All these possible mechanisms require further study.
3) Because zinc is important to induce resistance to infections, perhaps, independent of HIV and pathogens involved, the study of the existence of a parallelism between HIV and aging for infection recidivism represents an interesting tool for future research because recidivistic infections lead to death under both conditions (Pawlec and Solana 1997) . Indeed, although the use of HAART may have resolved the problem of possible reduction in recidivistic opportunistic infections in stage IV through possible major zinc bioavailability, zinc deficiency is present in aging and severe recidivistic infections at the bronchoalveolar level lead often to death in old individuals because of the poor efficacy of conventional antibiotic therapy (Lewis and Reeves 1994) . Thus, supplementation with zinc may also be beneficial in aging as resistance against severe recidivistic infections. 
